Zealand Pharma Surges on Promising Weight Loss Drug Trial Results
Zealand Pharma's stock surged 17% post-positive trial results for its weight loss drug, showing promising 8.6% average weight reduction. Analysts ...
- Latest
- Trending
Zealand Pharma's stock surged 17% post-positive trial results for its weight loss drug, showing promising 8.6% average weight reduction. Analysts ...
European stocks dipped Friday as tech and banks struggled amidst Carlsberg's slump and weak economic data, despite UK retail sales ...
Jazz Pharmaceuticals hits a hurdle as its essential tremor drug trial misses primary endpoint. Awaiting Parkinson's trial results for future ...
Esperion's stock downgraded by BofA due to rising competition from Merck's PCSK9 inhibitors. Analysts weigh in on efficacy and market ...
Robert Azelby sells $20,215 in ADC Therapeutics shares for tax reasons; holds 53,005 shares. Investors eye insider actions for future ...
"Iontronic tech shows promise in slowing malignant brain tumor growth by continuously delivering low-dose drugs, bypassing the blood-brain barrier."
"Day One Biopharmaceuticals enhances pipeline, acquiring global rights to promising PTK7-targeting cancer drug DAY301, begins trial soon."
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
"Discover 7 breakthrough biotech stocks poised to boost your portfolio in a sector projected to reach $521.6B by 2033. Learn ...
Aerovate Therapeutics stock downgraded by BTIG after AV-101 trial setback; mixed analyst views and future pivotal readouts crucial for investors.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.